Lab-testing group ALS's FY27 guidance looks credible to Jefferies, but not overly demanding. ALS expects mid-to-high single-digit revenue growth in FY27. It estimates the earnings risk from the Middle East conflict at A$5 million-A$10 million. "We see scope for stronger revenue and margin expansion from FY28 onward," analyst John Campbell says. That partly reflects AI and automation initiatives, while activity among junior miners is picking up. Also, ALS should get a full-year contribution from its new Sydney and Lima laboratories. Jefferies retains a hold call on ALS and lifts its price target by 6.1% to A$24.40/share. ALS ended Monday at A$21.83. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 18, 2026 18:43 ET (22:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.